Flawed Analysis: Fact-Checking the MSK Evidence Driven Drug Pricing Project Review of Congressional Concerns Regarding the Medicare Part B Drug Payment Model
Researchers from the Memorial Sloan-Kettering Cancer Center (MSK) Evidence Driven Drug Pricing Project have now released two reports on the Centers for Medicare & Medicaid Services (CMS) proposed Medicare Part B Drug Payment Model. While presented with authoritative titles and references, upon deeper inspection experts in community oncology have found that they present deeply flawed economic analyses and dangerous clinical recommendations.
In the most recent piece “Examining Congressional Comments Regarding Medicare’s Part B Pilot Proposal,” Dr. Peter B. Bach and his MSK co-authors provide another biased analysis of the impact of the proposal. This brief attempts to fact-check the report’s assumptions and show why Congressional concerns about the CMS Part B experiment are well deserved.